This opportunity is no longer accepting applications.
grant RFA-NS-25-010

Safety and Efficacy of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Lewy Body Dementia and Amyloid-Beta Pathology (U01 - Clinical Trial Required)

This grant opportunity is seeking applications for placebo-controlled clinical trials to evaluate the effectiveness and safety of FDA-approved monoclonal antibody therapies targeting amyloid in patients with mixed dementia, particularly focusing on Lewy Body Dementias (LBD). The trials should include individuals diagnosed with Alzheimer’s pathology biomarkers and a clinical diagnosis of LBD, s…

This RFA is soliciting applications proposing placebo-controlled, clinical trials to determine the efficacy and safety of FDA approved monoclonal antibody therapies directed against amyloid compared to placebo in diverse "mixed dementia" populations with a focus on Lewy Body Dementias (LBD). In …

Funding Source

Agency: National Institutes of Health
Sub-agency: National Institute of Neurological Disorders and Stroke
Program: SBIR

Awards & funding

Award Ceiling: $6.7M
Award Amount: $6.7M

Dates

Opportunity Released: May 21, 2024
Open for Submission: May 21, 2024
Submission Deadline: January 24, 2025
Application Window Closes: January 24, 2025

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.